JW Pharmaceutical Corporation (001065.KS)
KRW 29450.0
(-1.01%)
KRW 29450.0
(-1.01%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 748.52 Billion | 684.35 Billion | 606.58 Billion | 547.33 Billion | 511.33 Billion | 537.18 Billion |
| Cost of Revenue | 412.85 Billion | 396.39 Billion | 372.2 Billion | 369.81 Billion | 350.21 Billion | 340.14 Billion |
| Gross Profit | 335.67 Billion | 287.95 Billion | 234.37 Billion | 177.52 Billion | 161.11 Billion | 197.04 Billion |
| Operating Expenses | 238.91 Billion | 225.17 Billion | 203.17 Billion | 178.84 Billion | 180.13 Billion | 175.45 Billion |
| Selling, General and Administrative Expenses | 205.24 Billion | 126.73 Billion | 115.33 Billion | 92.51 Billion | 81.71 Billion | 91.55 Billion |
| Research and Development Expenses | 33.67 Billion | 33.73 Billion | 19.88 Billion | 22.94 Billion | 25.21 Billion | 21.26 Billion |
| Other Expenses | - | 64.7 Billion | 67.95 Billion | 63.38 Billion | 73.2 Billion | 881.19 Million |
| Cost and Expenses | 651.76 Billion | 621.57 Billion | 575.38 Billion | 548.65 Billion | 530.34 Billion | 515.59 Billion |
| Operating Income | 100.3 Billion | 62.96 Billion | 31.19 Billion | -5.47 Billion | -19.01 Billion | 21.58 Billion |
| Interest Expense | 12.56 Billion | 9.38 Billion | 7.33 Billion | 7.58 Billion | 11.27 Billion | 8.68 Billion |
| Income Tax Expense | 16.4 Billion | 15.5 Billion | 21.97 Billion | 2.07 Billion | -9.06 Billion | 2.17 Billion |
| Earnings before Tax | 54.21 Billion | 45.36 Billion | 20.53 Billion | -13.2 Billion | -34.33 Billion | 10.23 Billion |
| Net Income | 37 Billion | 31.89 Billion | -1.44 Billion | -15.27 Billion | -25.27 Billion | 8.05 Billion |
| Earnings Per Share Basic | 1426.36 | 1267.10 | -62.11 | -657.85 | -1088.93 | 298.53 |
| Earnings Per Share Diluted | 1426.36 | 1267.10 | -62.11 | -657.85 | -1088.93 | 298.53 |
| Weighted Average Shares Outstanding | 24.6 Million | 23.92 Million | 23.2 Million | 23.22 Million | 23.21 Million | 26.98 Million |
| Weighted Average Shares Outstanding (Diluted) | 24.6 Million | 23.92 Million | 23.2 Million | 23.22 Million | 23.21 Million | 26.98 Million |
| Gross Margin | 0.45 | 0.42 | 0.39 | 0.32 | 0.32 | 0.37 |
| EBIT Margin | 0.12 | 0.12 | 0.08 | 0.03 | -0.00 | 0.07 |
| Profit Margin | 0.05 | 0.05 | -0.00 | -0.03 | -0.05 | 0.01 |
| EBITDA | 89.22 Billion | 73.45 Billion | 45.12 Billion | 15.07 Billion | -2.86 Billion | 39.33 Billion |
| Earnings Before Tax Margin | 0.13 | 0.09 | 0.05 | -0.01 | -0.04 | 0.04 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 172.27 Billion | 180.59 Billion | 205.01 Billion | 748.52 Billion | 184.2 Billion | 185.92 Billion |
| Cost of Revenue | 101.15 Billion | 97.56 Billion | 110.79 Billion | 412.85 Billion | 102.23 Billion | 102.32 Billion |
| Gross Profit | 71.11 Billion | 83.02 Billion | 94.22 Billion | 335.67 Billion | 81.97 Billion | 83.59 Billion |
| Operating Expenses | 59.47 Billion | 56.76 Billion | 61.27 Billion | 238.91 Billion | -55.86 Billion | -63.01 Billion |
| Selling, General and Administrative Expenses | 50.04 Billion | 49.76 Billion | 51.49 Billion | - | 55.86 Billion | 63.01 Billion |
| Research and Development Expenses | 9.43 Billion | 7 Billion | 9.77 Billion | - | 8.29 Billion | 8.36 Billion |
| Other Expenses | -158.15 Billion | 864.94 Million | -8.28 Billion | -36.13 Billion | -111.72 Billion | -126.03 Billion |
| Cost and Expenses | 160.63 Billion | 154.33 Billion | 172.06 Billion | 651.76 Billion | 102.23 Billion | 102.32 Billion |
| Operating Income | 11.63 Billion | 26.26 Billion | 32.95 Billion | 96.76 Billion | 26.1 Billion | 20.57 Billion |
| Interest Expense | - | 2.82 Billion | 2.79 Billion | 12.56 Billion | 3.32 Billion | 4.05 Billion |
| Income Tax Expense | 2.25 Billion | 6.35 Billion | 455.57 Million | 16.4 Billion | 7.98 Billion | 2.61 Billion |
| Earnings before Tax | 10.46 Billion | 25.67 Billion | 24.89 Billion | 54.21 Billion | -9.92 Billion | 18.59 Billion |
| Net Income | 8.51 Billion | 20.08 Billion | 24.96 Billion | 37 Billion | -17.91 Billion | 14.42 Billion |
| Earnings Per Share Basic | 346.06 | 815.74 | 1035.40 | - | -767.96 | 531.00 |
| Earnings Per Share Diluted | 346.06 | 815.74 | 1035.40 | - | -767.96 | 541.62 |
| Weighted Average Shares Outstanding | 23.32 Million | 23.35 Million | 22.87 Million | 23.33 Million | 23.32 Million | 23.33 Million |
| Weighted Average Shares Outstanding (Diluted) | 23.32 Million | 23.35 Million | 22.87 Million | 23.33 Million | 23.32 Million | 23.33 Million |
| Gross Margin | 0.41 | 0.46 | 0.46 | 0.45 | 0.45 | 0.45 |
| EBIT Margin | 0.10 | 0.17 | 0.19 | - | 0.45 | 0.45 |
| Profit Margin | 0.05 | 0.11 | 0.12 | 0.05 | -0.10 | 0.08 |
| EBITDA | 16.37 Billion | 31.12 Billion | 38 Billion | - | 81.97 Billion | 83.59 Billion |
| Earnings Before Tax Margin | 0.07 | 0.15 | 0.16 | 0.13 | 0.14 | 0.11 |
BG
300671
ARV
002614
IMJS
SNX